A SIMPLE EFFORT TO ENHANCE SOLUBILITY AND DISSOLUTION RATE OF SIMVASTATIN USING CO-CRYSTALLIZATION


Iyan Sopyan, Achmad Fudholi, Muchtaridi Muchtaridi, Ika Puspitasari

Abstract


Objective: The main objective of this study was to explore co-crystallization as an effort to enhance the solubility of simvastatin (SV) using tartaric acid (TA) as co-former.

Methods: The simulation of molecular modeling of TA against SV has been done by in silico using auto dock 4.2. A preparation of co-crystal carried out by using solvent drops grinding (SGD) with an equimolar ratio. A co-crystal formed was confirmed by scanning electron microscopy (SEM), saturated solubility test, in vitro dissolution test, infrared spectrophotometry (FTIR), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC).

Results: The in silico studies showed that the interaction of TA and SV has synthon molecular by hydrogen bonding. An increasing of solubility and in vitro dissolution profile of co-crystal resulted as compared to the value of pure SV and its physical mixer. Characterizations of a co-crystal SV: TA (1: 1) including SEM, FTIR, PXRD, and DSC have indicated the formation of new solid crystal phase that different compared to SV, TA, and its physical mixture.

Conclusion: The co-crystallization has been used to enhance the solubility and dissolution of simvastatin. All characterization either in silico and in vitro has shown the formation of co-crystal SV: TA (1:1).


Keywords


Simvastatin, Co-crystal, Solubility, Dissolution

| PDF | HTML |

References


Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res 2003;20:1917–25.

Aakeröy CB, Forbes S, Desper J. Using co-crystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J Am Chem Soc 2009;131:17048–9.

Blagden N, De Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Delivery Rev 2007;59:617–30.

Hu J, Johnston KP, Williams RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 2004;30:233–45.

Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J 2009;11:740–6.

Murtaza G. Solubility enhancement of simvastatin: a review. Acta Pol Pharm 2012;69:581–90.

Zhang Y, Zhang J, Jiang T, Wang S. Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties. Int J Pharm 2011;410:118–24.

Mandal D, Ojha PK, Nandy BC, Ghosh LK. Effect of carriers on solid dispersions of simvastatin (Sim): physico-chemical characterizations and dissolution studies. Pharm Lett 2010;2:47–56.

Margulis-Goshen K, Magdassi S. Formation of simvastatin nanoparticles from microemulsion. Nanomed Nanotechnol Biol Med 2009;5:274–81.

Zimper U, Aaltonen J, Krauel-Goellner K, Gordon KC, Strachan CJ, Rades T. The influence of milling on the dissolution performance of simvastatin. Pharmaceutics 2010;2:419–31.

Hiendrawan S, Veriansyah B, Widjojokusumo E, Soewandhi SN, Wikarsa S, Tjandrawinata RR. Simultaneous co-crystalization and micronization of paracetamol-dipicolinic acid co-crystal by supercritical antisolvent (SAS). Int J Pharm Pharm Sci 2016;8:89–98.

Padrela L, Rodrigues MA, Velaga SP, Fernandes AC, Matos AH, de Azevedo EG. Screening for pharmaceutical co-crystals using the supercritical fluid enhanced atomization process. J Supercrit Fluids 2010;53:156–64.

Zaworotko M. Crystal engineering of co-crystals and their relevance to pharmaceuticals and solid-state chemistry. Acta Crystallogr 2008;64:11–2.

Schultheiss N, Newman A. Pharmaceutical co-crystals and their physicochemical properties. Cryst Growth Des 2009;6:2950–67.

Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Delivery Rev 2007;59:617–30.

Aakeröy CB, Salmon DJ. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm 2005;7:439–48.

Bethune SJ, Schultheiss N, Henck JO. Improving the poor aqueous solubility of nutraceutical compound pterostilbene through co-crystal formation. Cryst Growth Des 2011;11:2817–23.

Aakeröy CB, Fasulo M, Schultheiss N, Desper J, Moore C. Structural competition between hydrogen bonds and halogen bonds. J Am Chem Soc 2007;129:13772–3.

Miroshnyk I, Mirza S, Sandler N. Pharmaceutical co-crystals-an oportunity for drug product enhancement. Expert Opin Drug Delivery 2009;6:333–41.

Cinčić D, Friščić T, Jones W. A stepwise mechanism for the mechanochemical synthesis of halogen-bonded co-crystal architectures. J Am Chem Soc 2008;130:524–5.

Price SL. The computational prediction of pharmaceutical crystal structures and polymorphism. Adv Drug Delivery Rev 2004;56:301–19.

Karamertzanis PG, Kazantsev AV, Issa N, Welch GW, Adjiman CS, Pantelides CC, et al. Can the formation of pharmaceutical co-crystals be computationally predicted? 2. Crystal structure prediction. J Chem Theory Comput 2009;5:1432–48.

Dhumal RS, Kelly AL, York P, Coates PD, Paradkar A. Co-crystalization and simultaneous agglomeration using hot melt extrusion. Pharm Res 2010;27:2725–33.

Jung S, Choi I, Kim I. Liquid-assisted grinding to prepare a co-crystal of adefovir dipivoxil thermodynamically less stable than its neat phase. Crystals 2015;5:583–91.

Basavoju S, Boström D, Velaga SP. Indomethacin-saccharin co-crystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res 2008;25:530–41.

Dhumal RS, Biradar SV, Paradkar AR, York P. Ultrasound assisted engineering of lactose crystals. Pharm Res 2008;25:2835–44.

Dwi Setyawan RS. Preparation and characterization of artesunate-nicotinamide co-crystal by solvent evaporation and slurry method. Asian J Pharm Clin Res 2014;7 Suppl 1:62–5.

Alhalaweh A, Kaialy W, Buckton G, Gill H, Nokhodchi A, Velaga SP. Theophylline co-crystals prepared by spray drying: physicochemical properties and aerosolization performance. AAPS PharmSciTech 2013;14:265–76.

Takata N, Shiraki K, Takano R, Hayashi Y, Terada K. Co-crystal screening of stanolone and mestanolone using slurry crystallization. Cryst Growth Des 2008;8:3032–7.

Trask AV, Motherwell WDS, Jones W. Solvent-drop grinding: green polymorph control of co-crystallisation. Chem Commun 2004;7:890–1.

Basavoju S, Boström D, Velaga SP. Indomethacin-saccharin co-crystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res 2008;25:530–41.

Ikram NKK, Durrant JD, Zalaludin AS, Purwitasari N, Mohamed N, Rahim ASA, et al. A virtual screening aroach for identifying plants with anti H5N1 neuraminidase activity. J Chem Inf Model 2015;55:308–16.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.

Desiraju GR. Crystal and co-crystal. CrystEngComm 2003;5:466–7.

Braga D, Maini L, Grepioni F. Mechanochemical preparation of co-crystals. Chem Soc Rev 2013;42:7638–48.

Shan N, Toda F, Jones W. Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics. Chem Commun 2002;20:2372–3.

Etter MC, Reutzel SM. Hydrogen bond directed co-crystallization and molecular recognition properties of acyclic imides. J Am Chem Soc 1991;113:2586–98.

Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Delivery Rev 2007;59:603–16.

Good DJ, Rodríguez-Hornedo N. Solubility advantage of pharmaceutical co-crystals. Cryst Growth Des 2009;9:2252–64.

Dokoumetzidis A, Macheras P. A century of dissolution research: from noyes and whitney to the biopharmaceutics classification system. Int J Pharm 2006;321:1–11.

Jung S, Choi I, Kim I. Liquid-assisted grinding to prepare a co-crystal of adefovir dipivoxil thermodynamically less stable than its neat phase. Crystals 2015;5:583–91.

Pandya P, Gattani S, Jain P, Khirwal L, Surana S. Co-solvent evaporation method for enhancement of solubility and dissolution rate of poorly aqueous soluble drug simvastatin: in vitro-in vivo evaluation. AAPS PharmSciTech 2008;9:1247–52.

Parmar VK, Shah SA. Hydrochloride salt co-crystals: preparation, characterization and physicochemical studies. Pharm Dev Technol 2013;18:443–53.

Sanphui P, Goud NR, Khandavilli UR, Nangia A. Fast dissolving curcumin co-crystals. Cryst Growth Des 2011;11:4135–45.

Lu E, Rodríguez-Hornedo N, Suryanarayanan A. A rapid thermal method for co-crystal screening. CrystEngComm 2008;10:665–8.

Fayos J. Molecular crystal prediction approach by molecular similarity: data mining on molecular aggregation predictors and crystal descriptors. Cryst Growth Des 2009;9:3142–53.




About this article

Title

A SIMPLE EFFORT TO ENHANCE SOLUBILITY AND DISSOLUTION RATE OF SIMVASTATIN USING CO-CRYSTALLIZATION

Keywords

Simvastatin, Co-crystal, Solubility, Dissolution

Date

01-06-2016

Additional Links

Manuscript Submission

Journal

International Journal of Pharmacy and Pharmaceutical Sciences
Vol 8, Issue 8, 2016 Page: 342-346

Online ISSN

0975-1491

Statistics

165 Views | 331 Downloads

Authors & Affiliations

Iyan Sopyan

Achmad Fudholi
Departement of Pharmaceutical and Technolgy Formulation of University of Gadjah Mada, Yogyakarta, 55281, Indonesia.
Indonesia

Muchtaridi Muchtaridi

Ika Puspitasari


Article Tools



Refbacks

  • There are currently no refbacks.